Nastech Reports Positive PYY Nasal Spray Clinical Trial Data And Will Advance Obesity Clinical Program In 2007

... Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported positive results from a dose ranging study designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various doses of Nastech's proprietary PYY(3-36) nasal spray in obese subjects. The study identified doses for a long-term Phase 2 efficacy and safety clinical trial. [click link for full article] ...